Inventor
DENNIS MARK S
US59 patents
⚠️ This page may combine multiple inventors who share the name “DENNIS MARK S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GENENTECH INC
36 patentsUS7528236B2May 5, 2009
Humanized anti-beta7 antagonists and uses therefor
GENENTECH INC69 citations98
US5786328AJul 28, 1998
Use of kunitz type plasma kallikrein inhibitors
GENENTECH INC149 citations98
US5780265AJul 14, 1998
Kunitz type plasma kallikrein inhibitors
GENENTECH INC125 citations98
US9708406B2Jul 18, 2017
Anti-transferrin receptor antibodies and methods of use
GENENTECH INC87 citations97
US5880256AMar 9, 1999
Factor VIIa inhibitors from Kunitz domain proteins
GENENTECH INC75 citations96
US5863893AJan 26, 1999
Factor VIIa inhibitors from kunitz domain proteins
GENENTECH INC66 citations96
US5834244ANov 10, 1998
Factor VIIa inhibitors from Kunitz domain proteins
GENENTECH INC82 citations96
US5795954AAug 18, 1998
Factor VIIa inhibitors from Kunitz domain proteins
GENENTECH INC81 citations96
US7892550B2Feb 22, 2011
Anti-cmet antibodies
GENENTECH INC79 citations95
US7476724B2Jan 13, 2009
Humanized anti-cmet antibodies
GENENTECH INC103 citations95
US6113896ASep 5, 2000
Pharmaceutical compositions containing ecotin and homologs thereof
GENENTECH INC80 citations95
US5843895ADec 1, 1998
Pharmaceutical administration of ecotin homologs
GENENTECH INC64 citations95
US5719041AFeb 17, 1998
DNA encoding ecotin homologs
GENENTECH INC67 citations95
US6987088B2Jan 17, 2006
Compounds that bind HER2
GENENTECH INC42 citations93
US7989595B2Aug 2, 2011
Compositions and methods for the diagnosis and treatment of tumor
GENENTECH INC31 citations92
US10174124B2Jan 8, 2019
Anti-CD3 antibodies and methods of use
GENENTECH INC11 citations91
US7608681B2Oct 27, 2009
Methods and compositions for prolonging elimination half-times of bioactive compounds
GENENTECH INC24 citations90
US7084109B2Aug 1, 2006
FVIIa antagonists
GENENTECH INC27 citations89
US8889847B2Nov 18, 2014
Antibodies and immunoconjugates and uses therefor
GENENTECH INC5 citations84
US7687605B2Mar 30, 2010
Humanized anti-beta7 antagonists and uses therefor
GENENTECH INC9 citations84
US11007267B2May 18, 2021
Anti-CD3 antibodies and methods of use
GENENTECH INC8 citations83
US10865251B2Dec 15, 2020
Anti-CD3 antibodies and methods of use
GENENTECH INC6 citations83
US10808036B2Oct 20, 2020
Anti-transferrin receptor antibodies and methods of use
GENENTECH INC5 citations83
US10508151B2Dec 17, 2019
Anti-transferrin receptor antibodies and methods of use
GENENTECH INC7 citations83
US9975949B2May 22, 2018
Anti-CD79b antibodies and methods of use
GENENTECH INC13 citations83
US10501545B2Dec 10, 2019
Anti-CLL-1 antibodies and methods of use
GENENTECH INC6 citations82
US4512973AApr 23, 1985
Method for overcoming trypsin inhibition
GENENTECH INC25 citations82
US9593167B2Mar 14, 2017
Antibodies and immunoconjugates and uses therefor
GENENTECH INC4 citations73
US11732054B2Aug 22, 2023
Anti-CD3 antibodies and methods of use
GENENTECH INC1 citations72
US11530275B2Dec 20, 2022
Anti-CD3 antibodies and methods of use
GENENTECH INC1 citations72
US11186650B2Nov 30, 2021
Anti-CD3 antibodies and methods of use
GENENTECH INC1 citations72
US10640572B2May 5, 2020
Anti-CD3 antibodies and methods of use
GENENTECH INC2 citations72
US11008403B2May 18, 2021
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
GENENTECH INC3 citations71
US10941199B2Mar 9, 2021
Anti-CD79b antibodies and methods of use
GENENTECH INC0 citations62
US12466896B2Nov 11, 2025
Anti-CD3 antibodies and methods of use
GENENTECH INC0 citations61
US11466087B2Oct 11, 2022
Anti-CLL-1 antibodies and methods of use
GENENTECH INC0 citations61
DENALI THERAPEUTICS INC
6 patentsUS10143187B2Dec 4, 2018
Transferrin receptor transgenic models
DENALI THERAPEUTICS INC12 citations83
US11124567B2Sep 21, 2021
Anti-TREM2 antibodies and methods of use thereof
DENALI THERAPEUTICS INC16 citations81
US12162948B2Dec 10, 2024
Methods of engineering transferrin receptor binding polypeptides
DENALI THERAPEUTICS INC1 citations72
US11912778B2Feb 27, 2024
Methods of engineering transferrin receptor binding polypeptides
DENALI THERAPEUTICS INC2 citations72
US11795232B2Oct 24, 2023
Engineered transferrin receptor binding polypeptides
DENALI THERAPEUTICS INC2 citations72
US11612150B2Mar 28, 2023
Transferrin receptor transgenic models
DENALI THERAPEUTICS INC0 citations61
DENNIS MARK S
4 patentsUS8679490B2Mar 25, 2014
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
DENNIS MARK S77 citations97
US8449883B2May 28, 2013
Compositions and methods for the diagnosis and treatment of tumor
DENNIS MARK S12 citations83
US8436147B2May 7, 2013
Antibodies and immunoconjugates and uses therefor
DENNIS MARK S13 citations83
US8580928B2Nov 12, 2013
CDR-repaired antibodies
DENNIS MARK S6 citations73
WASHINGTON UNIVERSITY ST LOUIS
2 patentsFONG SHERMAN
1 patentUNIV WASHINGTON
1 patentShowing the top 50 of 59 patents by PatentIndex Score.